Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat

The inhibitor of anaplastic lymphoma kinase (ALK) crizotinib significantly increases survival in patients with ALK‐positive non‐small cell lung cancer (NSCLC). When evaluating crizotinib pharmacokinetics (PKs) in patients taking the standard flat oral dose of 250 mg b.i.d., interindividual PK variab...

Descripción completa

Detalles Bibliográficos
Autores principales: Hohmann, Nicolas, Bozorgmehr, Farastuk, Christopoulos, Petros, Mikus, Gerd, Blank, Antje, Burhenne, Jürgen, Thomas, Michael, Haefeli, Walter E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993319/
https://www.ncbi.nlm.nih.gov/pubmed/33222380
http://dx.doi.org/10.1111/cts.12921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993319/
https://www.ncbi.nlm.nih.gov/pubmed/33222380
http://dx.doi.org/10.1111/cts.12921

Ejemplares similares